Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.52 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.52 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | CDK9 | P50750 | 2/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.44 |
| ▸ | MELK | Q14680 | 1/20 | 0.44 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.44 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.44 |
| ▸ | CHUK | O15111 | 1/20 | 0.43 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30368907 | 1.00 | CYP11B1 (0.52) | CYP11B1CYP11B2PRKCZCYP2A6CDK9 | |
| SCHEMBL31595960 | 0.98 | CYP11B1 (0.50) | CYP11B1CYP11B2PRKCZCYP2A6CDK9 | |
| Hydrochloric Acid SCHEMBL2241644 | 0.98 | CYP11B1 (0.50) | CYP11B1CYP11B2PRKCZCYP2A6CDK9 | |
| SCHEMBL29547785 | 0.91 | CYP11B1 (0.56) | CYP11B1CYP11B2PRKCZCYP2A6CDK9 | |
| SCHEMBL484716 | 0.91 | CYP11B1 (0.56) | CYP11B1CYP11B2PRKCZCYP2A6CDK9 | |
| Ammonia Solution, Strong SCHEMBL27725592 | 0.89 | CYP11B1 (0.55) | CYP11B1CYP11B2PRKCZCYP2A6CDK9 | |
| Water SCHEMBL28177305 | 0.89 | CYP11B1 (0.55) | CYP11B1CYP11B2PRKCZCYP2A6CDK9 | |
| Biphenyl SCHEMBL27880420 | 0.81 | CYP11B1 (0.60) | CYP11B1CYP11B2PRKCZCYP2A6CDK9 | |
| Formic Acid SCHEMBL28223024 | 0.81 | CYP11B1 (0.47) | CYP11B1CYP11B2CYP2A6CDK9CCNT1 | |
| SCHEMBL28455526 | 0.79 | HIPK2 (0.53) | CYP11B1CYP11B2CYP2A6CDK9GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 367 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117800909-A | Synthetic method of nitrogen-containing aromatic heterocyclic methylamine | 北京六合宁远医药科技股份有限公司 | 2024-04-02 | — | — | CN | claimed |
| CN-113200941-B | Column aromatic hydrocarbon fluorescent adsorption material containing phenothiazine and preparation method thereof | 华东理工大学 | 2022-08-26 | — | — | CN | claimed |
| CN-113200941-A | Column aromatic hydrocarbon fluorescent adsorption material containing phenothiazine and preparation method thereof | 华东理工大学 | 2021-08-03 | — | — | CN | claimed |
| US-20260137677-A1 | PROTACS USEFUL AGAINST THE MAIN PROTEASE SARS-COV-2 | TOCRIS COOKSON LTD (GB) | 2026-05-21 | — | — | US | disclosed |
| CN-122036558-A | Gossypol derivative, preparation method thereof and application thereof in preparation of coronavirus 3CL protease inhibitor | 陕西盘龙药业集团股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-12552830-B2 | Steroidal compound derivatives as therapeutic agents | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-02-17 | — | — | US | disclosed |
| CN-121108048-A | Synthesis method of 7-aminoisoquinoline | 上海毕得医药科技股份有限公司 | 2025-12-12 | — | — | CN | disclosed |
| EP-4079724-B1 | 2-(2-CHLOROPHENYL)-N-(5-SULFAMOYLISOQUINOLIN-7-YL)ACETAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS P2X4 ANTAGONISTS FOR THE TREATMENT OF E.G. URINARY TRACT DISEASES | WUHAN LL SCIENCE & TECHNOLOGY DEVELOPMENT CO LTD (CN) | 2025-11-12 | — | — | EP | disclosed |
| US-12441708-B2 | Cereblon ligands and bifunctional compounds comprising the same | ARVINAS OPERATIONS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250313547-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS INC (US) | 2025-10-09 | — | — | US | disclosed |
| US-12435128-B2 | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-10-07 | — | — | US | disclosed |
| CN-1275979-A | Isoquinoline compounds useful as urokinase inhibitors | PFIZER (US) | 2000-12-06 | — | — | CN | disclosed |
| WO-2000071512-A1 | INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 2000-11-30 | — | — | WO | disclosed |
| WO-2000047554-A2 | INHIBITORS OF FACTOR Xa | COR THERAPEUTICS INC. (US) | 2000-08-17 | — | — | WO | disclosed |
| EP-1023268-A1 | ISOQUINOLINES AS UROKINASE INHIBITORS | Pfizer Limited (GB) | 2000-08-02 | — | — | EP | disclosed |
| EP-0975600-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | Akzo Nobel N.V. (NL) | 2000-02-02 | — | — | EP | disclosed |
| WO-1999020608-A1 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER LIMITED (GB) | 1999-04-29 | — | — | WO | disclosed |
| WO-1998047876-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | AKZO NOBEL N.V. (NL) | 1998-10-29 | — | — | WO | disclosed |
| EP-0632808-A1 | ANTIVIRAL PEPTIDES | Pfizer Limited (GB) | 1995-01-11 | — | — | EP | disclosed |
| WO-1993019059-A1 | ANTIVIRAL PEPTIDES | PFIZER LIMITED (GB) | 1993-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313547-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | CYP11B1 4434/4885CYP11B2 4416/4885PRKCZ 1206/4885 |
| US-12435128-B2 | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 | INMT, CARM1, KDM1B | CYP11B1 2100/4885CYP11B2 2623/4885PRKCZ 4190/4885 |
| US-20260137677-A1 | PROTACS USEFUL AGAINST THE MAIN PROTEASE SARS-COV-2 | XIAP, MDM2, SARS1 | CYP11B1 4443/4885CYP11B2 4376/4885PRKCZ 773/4885 |
| US-12552830-B2 | Steroidal compound derivatives as therapeutic agents | PGF, NR3C2, NR5A1 | CYP11B1 5/4885CYP11B2 19/4885PRKCZ 3072/4885 |
| US-12441708-B2 | Cereblon ligands and bifunctional compounds comprising the same | CRBN, CBL, MDM2 | CYP11B1 4434/4885CYP11B2 4416/4885PRKCZ 1206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.